SCHEDULE 13G/A: Armistice Capital and Steven Boyd Disclose 4.99% Stake in BIO-key International

Armistice Capital, LLC and Steven Boyd have filed an amended Schedule 13G, reporting a beneficial ownership of 4.99% in BIO-key International Inc.'s common stock as of December 31, 2024.

Summary

• Armistice Capital, LLC and Steven Boyd, collectively referred to as the 'Reporting Persons', have filed an Amendment No. 2 to Schedule 13G.
• The filing discloses their beneficial ownership in BIO-key International Inc. (Issuer) Common Stock, par value $0.0001 per share.
• As of December 31, 2024, the Reporting Persons collectively beneficially own 164,235 shares of BIO-key International Inc.
• This aggregate amount represents 4.99% of the Issuer's class of securities.
• Armistice Capital, LLC, a Delaware entity, acts as the investment manager for Armistice Capital Master Fund Ltd., the direct holder of the shares.
• Steven Boyd, a U.S. citizen, is the managing member of Armistice Capital, LLC.
• The shares are held with shared voting power and shared dispositive power by both Armistice Capital, LLC and Steven Boyd.
• The filing certifies that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of the issuer.

Sentiment

Score: 5

Explanation: The document is a factual disclosure of an ownership stake, providing neutral information without expressing positive or negative sentiment about the company's performance or prospects.

Positives

• A significant institutional investor, Armistice Capital, LLC, maintains a notable stake in BIO-key International, potentially indicating confidence in the company's long-term prospects.
• The filing explicitly states that the shares were acquired and are held in the ordinary course of business, not for the purpose of changing or influencing control, suggesting a passive investment approach.

Negatives

• The reported ownership percentage of 4.99% is just below the 5% threshold that would typically trigger more detailed reporting requirements (e.g., Schedule 13D), which might limit the transparency of future intentions if the stake were to increase slightly.

Future Outlook

This Schedule 13G filing does not contain any forward-looking statements or guidance from BIO-key International Inc. or the reporting persons regarding the company's future performance or strategic direction.

Industry Context

This filing is a standard disclosure of an institutional investor's passive stake in a publicly traded company. It does not provide specific insights into broader industry trends for identity and access management or biometric solutions, which are BIO-key International's primary business areas. However, it indicates continued investor interest in companies within this sector.

Stakeholder Impact

• Shareholders: Provides transparency regarding a significant institutional investor's stake, which can influence market perception and potentially liquidity.
• Company Management: Awareness of a notable passive investor on their shareholder register.

Key Dates

Keywords

BIO-key International, Armistice Capital, Steven Boyd, Schedule 13G, Beneficial Ownership, Common Stock, SEC Filing, Institutional Investor, Equity Stake, Investment Management